We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-0.73%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$841M
AUM Growth
-$257M
(-23%)
Cap. Flow
-$256M
Cap. Flow
% of AUM
-30.4%
Top 10 Holdings %
Top 10 Hldgs %
71.13%
Holding
232
New
70
Increased
34
Reduced
47
Closed
75
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$56.8M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$12.1M |
| 3 |
Cogent Biosciences
COGT
|
+$9.38M |
| 4 |
Incyte
INCY
|
+$7.38M |
| 5 |
Nektar Therapeutics
NKTR
|
+$3.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$58.4M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$9.06M |
| 3 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$6.4M |
| 4 |
MannKind Corp
MNKD
|
+$3.35M |
| 5 |
AbbVie
ABBV
|
+$3.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.86% |
| 2 | Consumer Staples | 0.43% |
| 3 | Consumer Discretionary | 0.12% |
| 4 | Materials | 0.09% |
| 5 | Technology | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $260M | 30.88% |
+9,867
| New | +$2.69M |
|
2
CALL
AstraZeneca
AZN
$267B
| $51.2M | 6.09% |
7,323
-150
| -2% | -$10.4K |
|
|
3
Biogen
BIIB
$30.4B
| $50.1M | 5.96% |
+182,898
| New | +$56.8M |
|
|
4
PUT
Biogen
BIIB
$30.4B
| $48.9M | 5.82% |
2,071
+1,841
| +800% | +$571K |
|
|
ESPR
5
PUT
DELISTED
Esperion Therapeutics
ESPR
| $43.8M | 5.21% |
6,053
+4,383
| +262% | +$322K |
|
6
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $43.7M | 5.19% |
+2,875
| New | +$348K |
|
|
7
CALL
iShares S&P 100 ETF
OEF
$19.8B
| $38M | 4.51% |
2,500
-1,705
| -41% | -$207K |
|
|
8
PUT
AstraZeneca
AZN
$267B
| $29.3M | 3.49% |
4,190
+434
| +12% | +$30.1K |
|
9
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $17.3M | 2.06% |
2,333
-6,690
| -74% | -$446K |
|
|
ZGNX
10
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $16.3M | 1.93% |
4,059
+969
| +31% | +$38.4K |
|
|
ODT
11
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $15.6M | 1.85% |
734,272
-91,179
| -11% | -$2.15M |
|
12
CALL
Merck
MRK
$326B
| $13.6M | 1.61% |
2,610
-16,487
| -86% | -$890K |
|
|
13
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $11.7M | 1.39% |
+44,500
| New | +$12.1M |
|
|
14
PUT
Incyte
INCY
$26B
| $10.8M | 1.28% |
1,295
+259
| +25% | +$23.4K |
|
15
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $9.84M | 1.17% |
+1,122
| New | +$102K |
|
|
16
CALL
Incyte
INCY
$26B
| $9.5M | 1.13% |
1,140
+608
| +114% | +$54.8K |
|
|
17
Cogent Biosciences
COGT
$6.95B
| $9.38M | 1.12% |
+210,963
| New | +$9.38M |
|
|
18
CALL
Nektar Therapeutics
NKTR
$2.39B
| $7.7M | 0.92% |
48
+11
| +30% | +$14.2K |
|
|
19
Incyte
INCY
$26B
| $6.82M | 0.81% |
+81,861
| New | +$7.38M |
|
|
ONCE
20
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $6.76M | 0.8% |
+1,015
| New | +$58.6K |
|
|
ALXN
21
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $6.61M | 0.79% |
593
+346
| +140% | +$41.4K |
|
|
22
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $6.58M | 0.78% |
888
-584
| -40% | -$38.9K |
|
|
SGMO
23
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $6.43M | 0.77% |
3,386
+656
| +24% | +$14K |
|
|
24
Nektar Therapeutics
NKTR
$2.39B
| $6.25M | 0.74% |
3,922
+2,589
| +194% | +$3.34M |
|
|
ONCE
25
CALL
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $5.16M | 0.61% |
+775
| New | +$44.8K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2018 Portfolio in Review
As of Q1 2018, Sabby Management held 232 positions worth $841M, down 23% from $1.1B the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Sabby Management withdrew a net $256M in Q1 2018, closing 75 positions and reducing 47 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $6.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 12% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
Against the trend, Sabby Management opened a new position in Biogen worth $50.1M.
- Sabby Management's largest Q1 2018 buy was Biogen: 182,898 shares worth $50.1M.
- Sabby Management added most to Nektar Therapeutics in Q1 2018, an estimated $3.34M increase.
- Sabby Management's biggest Q1 2018 reduction was Bristol-Myers Squibb, cutting an estimated $58.4M.
- Sabby Management fully exited Spark Therapeutics, Inc. Common Stock in Q1 2018, selling an estimated $6.4M.
- Sabby Management's ten largest holdings make up 71% of its $841M portfolio in Q1 2018.
- Sabby Management opened 70 new positions and closed 75 in Q1 2018.
- Sabby Management's portfolio value fell 23% quarter-over-quarter to $841M.
Based on Sabby Management's 13F filing for Q1 2018, filed 15 May 2018.